13 years of historical data (2012–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Coherus Oncology, Inc. trades at 6.7x earnings, 18% below its 5-year average of 8.1x, sitting at the 33rd percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 72%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $194M | $158M | $314M | $615M | $1.2B | $1.5B | $1.3B | $589M | $468M | $1.2B | $852M |
| Enterprise Value | $338M | $302M | $692M | $1.0B | $1.2B | $1.3B | $1.3B | $619M | $442M | $1.2B | $694M |
| P/E Ratio → | 6.68 | 5.52 | — | — | — | 10.73 | 14.64 | — | — | — | — |
| P/S Ratio | 0.73 | 0.59 | 1.22 | 2.91 | 3.69 | 3.05 | 3.70 | 378.26 | 300.50 | 6.21 | 28.37 |
| P/B Ratio | — | — | — | — | 12.32 | 5.16 | 12.52 | — | 15.99 | 64.89 | — |
| P/FCF | — | — | — | — | — | 9.88 | 85.24 | — | — | — | — |
| P/OCF | — | — | — | — | — | 9.41 | 46.47 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.13 | 2.69 | 4.89 | 3.69 | 2.79 | 3.73 | 398.01 | 284.11 | 6.08 | 23.10 |
| EV / EBITDA | — | — | — | — | — | 8.23 | 11.97 | — | — | — | — |
| EV / EBIT | — | 5.43 | — | — | — | 8.46 | 12.33 | — | — | — | — |
| EV / FCF | — | — | — | — | — | 9.03 | 85.95 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Coherus Oncology, Inc. earns an operating margin of -41.8%. Operating margins have expanded from -121.7% to -41.8% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0% | 56.0% | 38.2% | 66.8% | 82.4% | 92.1% | 95.2% | -107.9% | -10216.9% | -33.8% | -608.0% |
| Operating Margin | -41.8% | -41.8% | -79.0% | -121.7% | -80.8% | 32.9% | 30.3% | -13137.3% | -14918.8% | -61.0% | -729.2% |
| Net Profit Margin | 10.7% | 10.7% | -92.5% | -138.2% | -87.9% | 27.8% | 25.2% | -13453.7% | -15306.6% | -67.0% | -743.2% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -151.6% | 68.5% | 269.7% | — | -1004.4% | -2418.6% | -756.0% |
| ROA | 5.3% | 5.3% | -42.8% | -50.3% | -37.8% | 21.1% | 35.3% | -159.8% | -139.6% | -65.2% | -111.7% |
| ROIC | -85.3% | -85.3% | -65.7% | -101.7% | -154.3% | 85.9% | 149.2% | — | — | — | — |
| ROCE | -48.2% | -48.2% | -63.5% | -60.0% | -43.6% | 31.6% | 59.8% | -204.0% | -181.1% | -101.5% | -181.2% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $144M ($270M total debt minus $126M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 4.29 | 1.48 | 1.79 | — | 3.47 | 5.51 | — |
| Debt / EBITDA | — | — | — | — | — | 2.59 | 1.70 | — | — | — | — |
| Net Debt / Equity | — | — | — | — | 0.02 | -0.44 | 0.10 | — | -0.87 | -1.36 | — |
| Net Debt / EBITDA | — | — | — | — | — | -0.77 | 0.10 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -0.84 | 0.71 | — | — | — | — |
| Interest Coverage | -4.11 | -4.11 | -5.01 | -7.91 | -11.49 | 7.39 | 6.12 | -21.11 | -24.30 | -14.53 | -6638.39 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.21x means Coherus Oncology, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.75x to 1.21x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.21 | 1.21 | 1.43 | 2.75 | 3.64 | 5.27 | 2.98 | 2.18 | 4.47 | 2.22 | 1.49 |
| Quick Ratio | 0.96 | 0.96 | 1.24 | 2.47 | 3.42 | 4.97 | 2.90 | 2.13 | 4.47 | 2.30 | 1.53 |
| Cash Ratio | 0.45 | 0.45 | 0.35 | 1.38 | 2.52 | 3.72 | 1.55 | 2.18 | 4.47 | 2.22 | 1.49 |
| Asset Turnover | — | 0.60 | 0.41 | 0.44 | 0.48 | 0.57 | 0.87 | 0.02 | 0.01 | 1.07 | 0.14 |
| Inventory Turnover | 1.68 | 1.68 | 2.54 | 1.81 | 1.53 | 0.85 | 1.74 | 1.95 | — | — | — |
| Days Sales Outstanding | — | 167.26 | 369.65 | 190.18 | 137.51 | 120.47 | 145.55 | — | — | 3.57 | 18.95 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Coherus Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 15.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 15.0% | 18.1% | — | — | — | 9.3% | 6.8% | — | — | — | — |
| FCF Yield | — | — | — | — | — | 10.1% | 1.2% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $115M | $94M | $78M | $75M | $83M | $73M | $65M | $53M | $42M | $37M |
Compare CHRS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CHRSYou | $194M | 6.7 | — | — | 56.0% | -41.8% | — | -85.3% | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CHRS stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonCoherus Oncology, Inc.'s current P/E ratio is 6.7x. The historical average is 10.3x. This places it at the 33th percentile of its historical range.
Based on historical data, Coherus Oncology, Inc. is trading at a P/E of 6.7x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Coherus Oncology, Inc. has 56.0% gross margin and -41.8% operating margin.